argenx up 9% premarket on Q2 top and bottom line beats

Jul. 28, 2022 6:51 AM ETargenx SE (ARGX)By: Jonathan Block, SA News Editor1 Comment

Quarterly results


  • argenx SE (NASDAQ:ARGX) is up 9% premarket after its Q2 2022 results beat on the top and bottom lines.
  • The revenue beat was particularly staggering. The Danish biotech reported revenue of ~$85.2M, almost double the ~$43.2M consensus estimate.
  • While GAAP EPS of -$3.81 was also a beat, it represented an ~89% decline from the $2.02 achieved in the year-ago period.
  • Sales of Vygart (efgartigimod alfa-fcab) of $74.8M was a ~253% increase compared to Q2 2021.
  • argenx (ARGX) ended the quarter with ~$2.6B in cash and cash equivalents, an 11% increase from Dec. 31, 2021.
  • Seeking Alpha's Quant Rating views argenx (ARGX) as a hold with high grades for momentum, growth, and revisions.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.